Get notified of page updates
Enroll in Research > Research Search & Enroll Tool > Prostate Cancer Genetic Risk Evaluation and Screening Study (PROGRESS)
Prostate Cancer Genetic Risk Evaluation and Screening Study (PROGRESS)

Prostate Cancer Genetic Risk Evaluation and Screening Study (PROGRESS)

Clinicaltrials.gov identifier:
NCT05129605

Prevention
People at high risk for prostate cancer due to an inherited mutation

Study Contact Information:

For additional information, please contact:

Felicia Mett by phone: 857-238-3838
or by email: fmett@partners.org     


Prostate Cancer Genetic Risk Evaluation and Screening Study (PROGRESS)

About the Study

This study will look at how enhanced cancer screening using  will improve early detection rates and further understanding of how inherited mutations can lead to development of cancer.

What the Study Involves

Two groups of patients will be enrolled in this study:  

  • One group will enroll people who have an inherited mutation in one of the following genes: , ATR, , , , , , FANCA, GEN1, HOXB13, , , , , , , , ,
  • The other study group will enroll people who do not have an inherited genetic mutation, but who do have a strong family history suggestive of increased risk for cancer.

Both study groups will receive the same cancer screening tests:

  • physical exam (digital rectal exam)
  • prostate-specific antigen () test 
  • of the .

Study participants will be followed for up to 20 years.

Study Location

Massachusetts

  • Boston, MA
    Massachusetts General Hospital
    Lead Researcher: Keyan Salari, MD, PhD
    Study coordinator: Felicia Mett: 857-238-3838 or fmett@partners.org     
This Study is Open To:

Men age 35-74 years old who meet the following criteria may be eligible:

  • No prior diagnosis of cancer
  • Meets either group 1 or group 2 criteria:
    • Group 1: has an inherited mutation in one of the following genes: , ATR, , , , , , FANCA, GEN1, HOXB13, , , , , , , , , .
    • Group 2: has a strong family history suggestive of high genetic risk for cancer but with no inherited genetic mutation.
This Study is Not Open To:

Men are not eligible to participate if they:

  • have had a prior diagnosis or treatment of cancer
  • are not able to undergo a MRI or receive the contrast agent